Qiagen has announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) assays and customised molecular testing solutions for oncology and other disease areas, to expand the availability of dPCR assays for oncology research applications.
The combination of Qiagen’s global reach and automation expertise with the assay development and manufacturing capabilities of ID Solutions will strengthen Qiagen’s position in oncology research.
Under the agreement, ID Solutions will manufacture and supply dPCR assays for non-clinical research use on Qiagen’s QIAcuity platforms. These assays are optimised to simultaneously detect multiple mutations in cell-free DNA (cfDNA) from plasma and genomic DNA (gDNA) from formalin-fixed, paraffin-embedded (FFPE) tissue. Qiagen will commercialise these kits starting in Europe as the first region, with the potential for future expansion into other regions.
This agreement supports Qiagen’s strategic focus on accelerating the adoption of the QIAcuity dPCR platform in oncology research. The new assays expand Qiagen’s portfolio, complementing the existing PanCancer Kits for detecting multiple hallmark mutations in DNA from diverse sample types and over 200 LNA (locked nucleic acid) Mutation Assays available via its GeneGlobe platform. This unique platform integrates pre-designed assays with a database of more than 10,000 biological entities, including genes, miRNAs, pathogens and pathways.
